Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery

NCT: NCT05734157 · COMPLETED

NCT IDNCT05734157
StatusCOMPLETED
Start Date2022-02-17
Completion2025-08-27

Brief Summary

The CVT-SFA Trial investigates the inhibition of restenosis using the CVT Everolimus-coated PTA Catheter in the treatment of de-novo occluded/ stenotic or re-occluded/restenotic superficial femoral or popliteal arteries.

Frequently Asked Questions

What is CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery?

CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery is a clinical trial registered under NCT05734157. Current status: COMPLETED.

What is the status of NCT05734157?

The current status of NCT05734157 (CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery) is: COMPLETED.

When did CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery start?

CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery started on 2022-02-17.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑